Menu
We are an Innovative Therapeutic Apheresis company focused on cleansing patient blood of neutrophil extracellular traps (NETs).
WHAT WE DO
Santersus
We are developing a novel patent protected transformative, lifesaving, blood purification device, for use in the treatment of sepsis, autoimmune diseases, cancer and COVID-19.
Santersus AG has developed a unique strategy for the treatment of patients in a variety of therapeutic areas through the selective extra corporeal removal of NETs from blood, using our patented NucleoCapture apheresis device.
TEAM
Meet Santersus Team
The Company’s founders have an outstanding track record in realizing significant returns for their novel discoveries. The founders have collectively been responsible for over 15 patents and 30 publications with many of their patents leading to the formation of eight companies that have resulted in NASDAQ listings or acquisitions by some of the leading healthcare-pharma players.
Scott Maguire Non-Executive Chairman
Mr. Maguire has over 30 years of global life sciences and healthcare investment banking, management and board experience, raising well in excess of $1billion as an executive and an advisor.
Mr. Maguire is a co-founder and board member of Cannaray Limited. Cannaray is a medical cannabis and cannabodiol company, operating in the UK and Germany. After closing on a £7.8 million Series A raise, Cannaray through acquisitions quickly became Europe’s second largest (in terms of revenues) cannabis company.
Having been Chairman and CEO of Xenetic Biosciences Inc (XBIO), Mr. Maguire turned a life science start-up with a collection of patents into a clinical stage company listed on NASDAQ, a listing he led in 2016. Mr Maguire raised approximately $35M from the private and public markets as well as $20M from strategic investors and has transacted license agreements for Xenetic worth $178M.
Mr. Maguire was a co-founder and board member of UK dialysis services, Renal Services Ltd. He led the fundraising from seed capital to Series C. Renal Services became the second largest private provider of dialysis services in the UK. The business was exited via a trade sale to DaVita Inc in late 2020.
In 2002 he founded Healthcare Capital Partners Ltd, a healthcare and life science corporate finance and proprietary investment boutique which has been responsible for hundreds of millions in investments and exits since its founding. In 1996, he co-founded the Arthur Andersen global healthcare/life sciences corporate finance practice based in London which he assisted in building from 2 to 35 bankers globally. Scott started his banking career on Wall Street with Merrill Lynch in 1987.
Dmitry Genkin Non-Executive Director
Since 2006, Dr. Genkin has served as the Chairman of the Board of Pharmsynthez plc (MICEX: LIFE), an Eastern European pharmaceutical company specializing in the development of oncology drugs and manufacture of science-intensive substances. Since 2002, Dr. Genkin has served as a director of and on the scientific advisory board of Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company focused on developing next generation biologic drugs and novel oncology therapeutics. Dr Genkin is co-founder and former director of VBI Vaccines Inc (NASDAQ: VBIV) – a clinical-stage biopharmaceutical company.
Moshe Mizarahy Non-Executive Director
Moshe Mizrahy co-founded InMode Ltd. (NASDAQ:
INMD) in 2008 and has been our Chief Executive
Officer and Chairman of the board of directors since
inception. Prior to that, Mr. Mizrahy was co-founder
and chief executive officer of Syneron Medical Ltd., a
medical aesthetic device company based in Israel. Mr.
Mizrahy was also the former chief executive officer of
Home Skinovations Ltd., an international medical
aesthetic consumer devices company active in the
home use market and is currently the chairman of its
board since 2007
In addition to Home Skinovations Ltd., Mr. Mizrahy
currently sits on the board of directors of the following companies: SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Easy-Lap Ltd, O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., New Forest Wood Products (2012) Ltd., M.N. Business Strategy Ltd., Silk’n Cure Ltd. and Himalaya Family Office Advising Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
David Onions Non-Executive Director
David Onions is a board director of Santersus Ag and Dxcover Ltd. and Chief Scientific Adviser to Norcliffe Capital.
Formerly, David was Professor Veterinary Pathology and Director of the Leukaemia Research Fund’s (Ian Botham) Virus Centre at the University of Glasgow. He founded 2 Biotechnology companies Q-One Biotech and BioOutsource which were acquired for a total of $100M. He became CMO of one of the acquirers, Invitrogen, and was involved in the leveraged buyout of their BioReliance division which was subsequently acquired for $350M and is now part of Merck KGaA.
He was a member of several advisory groups including the UK Advisory Committee on Release of GMOs Into the Environment (ACRE), the FDA xenotransplantation advisory committee, The World Health Organisation’s Expert Advisory Panel on Biological Standardization and the UK Medical Research Council Stem Cell Foundation. He has been on the scientific advisory groups of leading companies including Novartis, Baxter, and Merck KGaA.
David was awarded the Norman Hall Gold Medal for Research into Animal Diseases from the Royal College of Veterinary Surgeons, the Animal Health Trust Award for Outstanding Scientific Achievement and The British Veterinary Association’s Cup and Medal for contributions to veterinary science. In 2006 he received Honorary Doctorate (DVMS) from the University of Glasgow for services to biotechnology and veterinary medicine.
He is a Fellow of the Royal Society of Edinburgh, Fellow of the Academy of Medical Sciences and a Fellow of the Royal Society of Arts.
James Ladtkow Chief Executive Officer
James Ladtkow brings visionary leadership and a wealth of expertise in medical device development from early concept through commercialization to the Santersus team. James has worked in all phases of medical product development from early ideation through clinical testing and market introduction for major medical device manufacturers like Terumo. While at Terumo, Mr. Ladtkow was instrumental in the design and clinical approval of the “gold standard” therapeutic apheresis system, Spectra Optia ™. James also led development teams for the Rika, plasma collection system recently released in the US by Terumo BCT. Mr. Ladtkow was regarded as a dynamic leader and mentor, seeking to advance and build capability within his fellow Engineers. He is also known for his innovative mind and led the advanced engineering/ new product ideation team at Terumo BCT. He has successfully led large technical teams and managed multimillion-dollar projects within the highly regulated medical device industry. James holds a bachelor’s degree in Mechanical Engineering from The University of Colorado, College of Engineering and Applied science as well as an MBA from Colorado Christian University.
Aleksander Zaporoztsev Chief Financial Officer
Aleksander Zaporoztsev joined Santersus AG team
with over 20 years of financial experience, 10 of those
years of financial and management expertise in the
biopharmaceutical industry.
Mr. Zaporoztsev is a board member of EPhaG AS,
Kevelt Pharmaceuticals OY and PJSC Pharmsynthez
(MOEX: LIFE) and serves as a chairman of Audit
Committee at AS PRFoods (Nasdaq: PRF1T) and at PJSC Pharmsynthez. Since 2009, Aleksander has held various administrative roles in portfolio companies of Amber Trust S.C.A., a private equity fund.
Aleksander is a partner at FINARTE OU, a financial and
management advisory firm.
Prior to joining Amber Trust S.C.A., Mr. Zaporoztsev
held multiple financial and administrative positions
at the biggest industrial holdings in the Baltic States
– BLRT Grupp AS, focused on marine industries and
headquartered in Tallinn, Estonia. Aleksander’s
earlier experience includes a number of
senior financial and management positions at
financial and industrial companies in the Baltic
States.
Mr. Zaporoztsev is a strategic finance executive with
extensive experience in budgeting and reporting,
domestic and international finance,
strategic planning, cash flow management,
accounting (incl. IFRS), taxation, treasury
and business development.
Andrew Daniel Aswani Chief Medical Officer
MD, PhD (London), MRCP (London), FRCA (UK), EDIC,
FFICM.
Dr Aswani serves as Chief Medical Officer. He is
Consultant in Intensive Care Medicine & Anaesthesia
at Guy’s and St Thomas’ NHS Foundation Trust,
London. He is also Consultant in Intensive Care
Medicine at London Bridge Hospital (HCA). Dr Aswani
has been dedicated to a top tier career in Intensive
Care Medicine and Anaesthesia since 2001. Dr Aswani
is the Clinical Lead for Junior Doctors and the Clinical
Lead for Vascular Access at Guy’s and St Thomas’. He is Scientific Advisory Board member of Cannaray Ltd.
Dr Aswani undertook extensive training in multiple
specialties in the leading clinical institutions in
Manchester, Sydney and London. He completed his
PhD thesis at Queen Mary University of London
(2010-2016) where he studied the role of cell-free
circulating DNA released into the circulation in shock
states to explain sterile organ injury and death. Dr
Aswani introduced a novel therapeutic agent to bind
circulating cell-free DNA that resulted in multiple
organ protection and improved survival. Dr Aswani
continues to perform research in this field and has
recently completed preclinical studies for Santersus
Ltd.
WORK WITH US
Careers
If you would like to join us in our revolutionary journey, please send your CV.
Investors
If you would like to join us in our revolutionary journey, please send your requests for further information.
Collaborations
If you would like to join us in our revolutionary journey, please send us your collaboration
and academic proposals.